Mar 4, 2013 by Brian Orelli, PhDWhen Will This Obesity Drug Launch?Eight months after approval, Arena's investors are still waiting for Belviq to launch.
Mar 1, 2013 by Brian Orelli, PhDDense Fog Over Amarin's EarningsInvestors get little insight into how Vascepa's launch is going.
Feb 28, 2013 by Brian Orelli, PhD101 Reasons to Stay Away From Drugs for This DiseaseAlzheimer's disease drugs have a high failure rate.
Feb 28, 2013 by Brian Orelli, PhDShould You Buy These Oversized Biotechs?They'll need a lot more revenue growth to double again.
Feb 28, 2013 by Brian Orelli, PhDDon't Forget About Pharma's StepchildA look at consumer health divisions.
Feb 28, 2013 by Brian Orelli, PhDWhy Is the Blockbuster Model Breaking?There's hope for pharma regardless.
Feb 27, 2013 by Brian Orelli, PhDExpanded Approval Isn't a Sure ThingAmarin's data supporting expanded approval for Vascepa look good, but will the FDA want more?
Feb 27, 2013 by Brian Orelli, PhDWhat Makes Biogen Idec One of America's Best Companies Biogen Idec is one of the 25 Best Companies in America.
Feb 26, 2013 by Brian Orelli, PhDCost Cutting Is Nice, But Don't Forget About SalesDendreon needs to grow the top line AND cut costs.
Feb 26, 2013 by Brian Orelli, PhDWinner, Loser, and a Lesson From This Biotech's DemiseRecalling Affymax's Omontys affected more than just the biotech and its partner.
Feb 25, 2013 by Brian Orelli, PhDJust 12,500% More Growth for an Obesity BlockbusterVIVUS' obesity drug Qsymia continues on its slow launch.
Feb 25, 2013 by Brian Orelli, PhDThe Fight Over This Biotech's CashInvestors would be best to watch the fight between Elan and Royalty Pharma from the sidelines.
Feb 22, 2013 by Brian Orelli, PhDFinally Approved! Now, About Those Sales...Roche and ImmunoGen's T-DM1, now called Kadcyla, gains FDA approval.
Feb 21, 2013 by Brian Orelli, PhDFDA Whiplashes This BiotechChelsea's Northera might be approvable after all.
Feb 19, 2013 by Brian Orelli, PhDMore Positive Data for Gilead's Hep C TreatmentNext step: submitting application for approval.
Feb 19, 2013 by Brian Orelli, PhDThe FDA Made Biotech Investing Harder (But More Lucrative)The FDA is getting looser with approvals.
Feb 15, 2013 by Brian Orelli, PhDBetter Buy: Pfizer or Zoetis?Animals or humans? Stability or innovation?
Feb 15, 2013 by Brian Orelli, PhDGlaxoSmithKline and Pfizer's HIV Joint Venture Gets Priority Review for DolutegravirThe FDA will review the ViiV Healthcare drug by Aug 17.
Feb 15, 2013 by Brian Orelli, PhDSanofi's Orphan Drug Eliglustat Tartrate Successful in 2 Late-Stage TrialsThe oral drug may replace Sanofi's Cerezyme that has to be injected.
Feb 15, 2013 by Brian Orelli, PhDBetter Dividend: Merck or Pfizer?You have to look beyond the dividend yield.
